Meera Mohan, MBBS

Peer-Reviewed Articles

1. Noveihed A, Hadidi SA, Mohan M, Shah MR. Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort. Br J Haematol 207(5):2161-2166, 2026. e-Pub 2026. PMID: 41251392.
2. Vega G, Morillo D, Riedhammer C, Bag A, Julian K, Gomis NT, Gaisan CM, Bermudez MA, Shah MR, Mohyuddin GR, Dhakal B, Rasche L, Schinke C, D’Souza A, Szabo A, Chakraborty R, Mohan M. Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma. Hemasphere 10(6):e70396, 2026. e-Pub 2026.
3. Mohan M, Radhakrishnan S, Schinke C, Katodritou E, Fonseca R. Reassessing The Duration of Induction Therapy for Newly Diagnosed, Transplant-Eligible Myeloma Patients in The Context of Quadruple CD38 Monoclonal Antibody-Based Regimens: Is 24 Weeks Optimal?. Am J Hematol 101(5):1141-1147, 2026. e-Pub 2026. PMID: 41588844.
4. Banerjee R, Mohan M, Shah B, Prince P, Gautam N, Conroy B, Beebe E, Pajerowski W, Cantu C, Meiseles H, Hughes D, Nador G, Hlavacek P, Sandin R, Li B, Meche A, Kim CH, Cruz IP, Sumaya M, DiBonaventur M. Real-World Treatment Patterns of Patients with Multiple Myeloma Initiating Elranatamab. Future Oncol 22(11):1331-1340, 2026. e-Pub 2026. PMID: 42021581.
5. Banerjee R, Mohan M, Shah B, Prince P, Gautam N, Conroy B, Beebe E, Pajerowski W, Cantu C, Meiseles H, Hughes D, Nador G, Hlavacek P, Sandin R, Li B, Meche A, Kim CH, Cruz IP, Sumaya M, DiBonaventura M. Real-World Treatment Patterns of Patients with Multiple Myeloma Initiating Elranatamab: Interim Results from the ALTITUDE-1 and ALTITUDE-2 Studies 22(11):1331-1340, 2026. e-Pub 2026. PMID: 42021581.
6. Hansen DK, Dima D, Devos J, Brazauskas R, Oloyede T, Afrough A, Ahmed N, Anderson L, Banerjee R, Berdeja JG, Bidikian A, Dhakal B, Dias A, Efebera Y, Faisal MS, Gowda L, Hashmi H, Mian H, Mirza S, Mohan M, Narra R, Rosko A, Schroeder M, Nishihori T, Landau H, Usmani S, Pasquini MC, Akhtar OS, Sidana S, K Patel AK. Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: A CIBMTR registry study. Blood Cancer J 9(15):4016-4022, 2026. e-Pub 2026.
7. Schjesvold F, Spencer A, Cohen YC, Ocio EM, Lopez-Pardo J, Cafro AM, Callander NS, Kaufman JL, Mohan M, Wermke M, Doki N, Kan R, Milanez-Almeida P, Stein A, Trabucco G, Ye S, Kulec K, Sechaud R, Banerjee S, Zhong H, Lai C, Rauch P, Raab MS. Final clinical data of a phase I dose-escalation study of WVT078 alone and in combination with WHG626 in patients with relapsed and/or refractory multiple myeloma 132(7):e70341, 2026. e-Pub 2026. PMID: 41880322.
8. Chunara F, Lemieux M, Szabo A, Mohan M, Mohyuddin GR. The association of age with adverse event profile for bortezomib and carfilzomib: A population-based analysis using the TriNetX Platform. Am J Hematol 101(8):2028-2032, 2026.
9. Aughey E, Estrada-Merly N, Akhtar O, Dhakal B, Mohan M, Narra R, Pasquini M, D’Souza A. Changes in Patient-reported Distress and Symptom Burden During Talquetamab Therapy in Multiple Myeloma. Br J Haematol 208(5):1836-1840, 2026. e-Pub 2026. PMID: 41797476.
10. Mainou M, Alsadhan M, Tsapa K, Visram A, Mian H, Popat R, Mai EK, Chakraborty R, Hadidi SA, Mohan M, Szabo A, Oekelen OV, Scheffer Cliff ER. Optimizing drug development strategies in oncology: a systematic review of 22 years of randomized controlled trials in multiple myeloma. J Natl Cancer Inst 118(3):448-458, 2026. e-Pub 2026. PMID: 41206930.
11. Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini M, Radhakrishnan S, Dhakal B, D’Souza A, Lin D, Ho C, Kurzrock R. Plasma Cell Leukemia: Genomic Features and Their Potential Relevance for Exploring Clinical Actionability. Blood Adv 10(4):1400-1404, 2026. e-Pub 2026. PMID: 41411484.
12. Hadidi SA, Lal BM, Bag A, Zhen S, Szabo A, Ogunsesan Y, Annyapu E, Dhakal B, Bhutani D, Thanendrarajan S, Zangari M, D’Souza A, Lentzsch S, Rhee FV, Chakraborty R, Schinke C, Mohan M, Shah MR. Talquetamab in Relapsed Refectory Multiple Myeloma: Multi-institutional Real-World Study. Blood Cancer J 15(1):196, 2025. e-Pub 2025. PMID: 41203605.
13. Mohan M, Schinke C. How can the application of a stem cell boost allow multiple myeloma patients to undergo further therapy after progression from CAR T-cell therapy?. Expert Rev Hematol:9-15, 2025. e-Pub 2025.
14. Henley EC, Uttley HA, Morris KE, Awoyinka I, Irwin MR, Costanzo ES, Winston D, D’Souza A, Stolley M, Dhakal B, MS, Mohan M, Pasquini MC, Cole SW, Doerwald ES, Rumble ME, Hillard CJ, Szabo A, Rao S, Knight JM. Mindfulness vs. sleep education for multiple myeloma patients during autologous HCT: feasibility of a randomized controlled pilot study 47:101540, 2025. e-Pub 2025.
15. Vandenboom H, Akhtar O, Szabo A, Narra R, Mohan M, D’Souza A, Pasquini M, Dhakal B. Safety and Efficacy of CAR-T vs. bispecific antibody against B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma: A systematic review and meta-analysis. Haematologica 111(2):745-750, 2025. e-Pub 2025. PMID: 40820831.
16. Banerjee R, Mohan M, Rejeski K, Puliafito B, Cirstea D, Kaur G, Midha S, Kumar NM, McCaughan G, Mehra N, Raje N. IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levels. Blood Adv 9(18):4720-4726, 2025. e-Pub 2025. PMID: 40690761.
17. Shrestha A, Thanendrarajan S, Bag A, MD, Dhakal B, Zangari M, Al-Hadidi S, Suzanne Lentzsch MD, Rhee FV, D’Souza A, Chakraborty R, Shah N, Shah MR, Mohan M, Schinke C. The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell 9(19):4806-4809, 2025. e-Pub 2025. PMID: 40674710.
18. Yadav K, Mohan M, Wagner C, Chakraborty R, Sborov D, Amandeep, Godara, McClune B, Schinke C, Dhakal B, D’Souza A, Szabo A, Mohyuddin GR. Patterns Of Relapse in Patients with Multiple Myeloma Receiving Chimeric Antigen Receptor T-Cell Therapy. Leukemia 39(9):2289-2291, 2025. e-Pub 2025. PMID: 40670671.
19. Mohan M, Szabo A, Cheruvalath H, Clennon A, Bhatlapenumarthi V, Patwari A, Balev M, Bhutani D, Shrestha A, Thanendrarajan S, Dhakal B, Zangari M, Trikannad A, Vellanki S, Al-Hadidi S, Lentzsch S, Rhee FV, Bag A, D’Souza A, Shah N, Chakraborty R, Shah MR, Schinke C. Intravenous Immunoglobulin (IVIG) Supplementation Improves Mortality in Recipients of BCMA Directed Bispecific Antibody Therapy. Blood Cancer J 15(1):74, 2025. e-Pub 2025. PMID: 40268898.
20. Vasudevan S, Lal BM, Vojjala N, Mohan M. Addressing Practical Challenges with Bispecific Antibody Therapy in Multiple Myeloma. Expert Opin Biol Ther 25(6):607-613, 2025. e-Pub 2025. PMID: 40247652.
21. Krishnan AY, Patel KK, Mohan M, Jagannath S, Niesvizky R, Silbermann RW, Yu Z, Wu L, Long T, McDonnell SR, Berg D, Stockerl-Goldstein KE. Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma. Blood Neoplasia 1(4):100043, 2024. e-Pub 2024. PMID: 40552138.
22. Yohay S, Oloyede T, Kim S, Fang X, Dhakal B, Aijaz A, Mohan M, Narra R, Pasquini M, D'Souza A, Hamadani M, Freeman CL, Akhtar OS. Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma. Br J Haematol 205(6):2370-2375, 2024. e-Pub 2024. PMID: 39396814.
23. Wu JF, Estrada-Merly N, Dhakal B, Mohan M, Narra RK, Pasquini MC, D'Souza A. . Racial and Ethnic Disparities in Autologous Hematopoietic Cell Transplantation Utilization in Multiple Myeloma Have Persisted Over Time Even After Referral to a Transplant Center. Transplant Cell Ther 30 Please don't let me go(12):1189.E1-1189.E.10, 2024. e-Pub 2024. PMID: 39277111.
24. Davis, McGann M, Furqan F, Mohan M, Rashid A, Abdallah A, Shune L, Mushtaq MU, Raza S, McGuirk J, Hamadani M, Anwer F, Hashmi H, Ahmed N. Timing of Toxicities and Non-relapse Mortality Following CAR T Therapy in Myeloma. Transplant Cell Ther 30(9):876-884, 2024. e-Pub 2024. PMID: 38871056.
25. Akhtar OS, Arshad S, Lian Q, Ahn KW, Binod Dhakal AD, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M. Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation. Transplant Cell Ther:S2666-6367(24)00668-7, 2024. e-Pub 2024. PMID: 39303985.
26. Akhtar OS, Aniko Szabo P, Bhatlapenumarthi V, Forsberg M, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Patel T, Shrestha A, Al-Hadidi S, Cooper D, Lentzsch S, Rhee FV, Shah M, D’Souza A, Schinke C, Chakraborty R, Shah N, Mohan M. Immune Prognostic Score Predicts Risk of Infection and Survival Outcomes in Patients with Relapsed Multiple Myeloma Treated with Bispecific Antibodies. Br J Haematol 205(5):1830-1834, 2024. e-Pub 2024. PMID: 39192546.
27. Gong Z, Khosla M, Vasudevan S, Mohan M. Current Status on Management of Primary Plasma Cell Leukemia. Curr Oncol Rep 26(9):1104-1112, 2024. e-Pub 2024. PMID: 38954316.
28. Mohan M, Schinke C. Risk Stratification in Multiple Myeloma: Are we there yet?. Br J Haematol 204(5):1585-1587, 2024. e-Pub 2024.
29. Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Rhee FV, D’Souza A, Chakraborty R, Schinke C, Mohan M. Changing Spectrum of Infection with BCMA and GPRC5D Targeting Bispecific Antibody Therapy in Patients with Relapsed Refractory Multiple Myeloma. Haematologica 109(3):906-914, 2024. e-Pub 2024. PMID: 37646658.
30. Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, Radhakrishnan SV, Chakraborty R, Rasche L, Schinke C, D’Souza A, Mohan M. The Effect of Stem Cell Infusion on Immune Effector Cell Associated Hematotoxicity with BCMA CAR T Cell Therapy in Multiple Myeloma. Blood Cancer J 14:16, 2024. e-Pub 2024.
31. Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin GR. Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J 14(1):20, 2024. e-Pub 2024. PMID: 38272897.
32. Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah N, Abedin S, Runaas L, Fenske T, Pasquini M, Shaw BE, Drobyski WR, Saber W, D’Souza A, Dhakal B, Mohan M, Longo W, Hamadani M. Severity and Organ Distribution of Chronic Graft-Versus-Host Disease with Posttransplant cyclophosphamide-based versus Methotrexate/Calcineurin inhibitor-based Allogeneic Hematopoietic Cell Transplantation. Bone Marrow Transplant 29(3):373-379, 2024. e-Pub 2024. PMID: 38177221.
33. Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, Rhee FV, D’Souza A, Szabo A, Carolina Schinke MD, Chakraborty R. Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study. Blood Cancer J 14(1):35, 2024. e-Pub 2024. PMID: 38443345.
34. Chakraborty R, Cheruvalath H, Patwari A, Schinke C, Dhakal B, Lentzsch S, D’Souza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Harrison SJ, Scheffer Cliff ER, Mohan M. Sustained Disease Remission Following a Finite Duration of Bispecific Antibody Therapy in Patients with Relapsed Refractory Multiple Myeloma. Blood Cancer J 14(1):137, 2024. e-Pub 2024. PMID: 39134535.
35. Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, D’Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M. Outpatient Administration of Commercial anti-CD19 and anti-BCMA CAR T-cell Therapies Using a Strategy of No Remote Monitoring and Early Cytokine Release Syndrome Intervention. Blood Adv 8(16):4320-4329, 2024. e-Pub 2024.
36. Hammons L, Zamora A, Haider S, Portuguese A, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah N, Hamadani M, D’Souza A, Hari P, Dhakal B. Chimeric antigen receptor and bispecific engager T-cell therapies in multiple myeloma patients with prior allogeneic transplantation. Br J Haematol 204(3):887-891, 2023. e-Pub 2023. PMID: 38054558.
37. Mohan M, Kothari A, Verhagen N, Shreenivas A, Radhakrishnan SV, Dhakal B, Figueroa-Castro C, Chhabra S, Janz S, Pasquini M, Hamadani M, Szabo A, D’Souza A. Blood and Marrow Transplant Within Four Weeks of SARS-CoV-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study. Bone Marrow Transplant 59(1):121-124, 2023. e-Pub 2023. PMID: 37803198.
38. Mohan M, Chakraborty R, Bal S, Baljevic M, D’Souza A, Berdeja JG, Callander N, Costa LJ. Recommendations on Prevention of Infections in Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma. Br J Haematol 203(5):736-746, 2023. e-Pub 2023. PMID: 37287117.
39. Mian A, Ahmad Naqvi SA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Riaz IB, Chakraborty R. Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: a systematic review and meta-analysis. Leuk Res, 2023. e-Pub 2023. PMID: 37285641.
40. Abdallah A, Mahmoudjafari Z, Ahmed N, Cui W, Shune L, McGuirk J, Mohan M, Mohyuddin GR, Afrough A, Alkharabsheh O, Atrash S. Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma. Eur J Haematol, 2023. e-Pub 2023. PMID: 36752328.
41. Kleman A, Singavi A, Pommert L, Matheson A, Hari P, Dhakal B, Mohan M, Janz S, Knight J, Shah M, Schinke C, Burns R, Rao S, Carlson K. A Timeline of Genetic Variant Enrichment-From Multiple Myeloma Diagnosis to Myeloma-Associated Myeloid Malignancy Variant Evolution in Myeloma-Associated MDS/AML. Blood Adv 7(18):5549-5553, 2023. e-Pub 2023. PMID: 36724511.
42. Hashmi H, Shebli A, Jain J, Khasawneh G, Mohan M, Mahmoudjafari Z, Cu W, McGuirk J, Shune L, Nausheen, Ahmed, Abdallah A. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd alone for patients with Relapsed Refractory Multiple Myeloma. Transplant Cell Ther 29(4):262E.1-262.E6, 2023. e-Pub 2023. PMID: 36682468.
43. Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardhan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D’Souza A, Zangari M, Rhee FV, Mohan M. Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR-T Therapy. Bone Marrow Transplant, 2022. e-Pub 2022. PMID: 36550200.
44. Abdallah A, Mahmoudjafari Z, Atieh T, Ahmed N, Cui W, Shune L, Mohan M, McGuirk J, Remker C, Foss M, Karloff E, Fitch H, Atrash S. Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination. Eur J Haematol 109(5):458-464, 2022. e-Pub 2022. PMID: 35810359.
45. Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Thanendrarajan S, Janz S, Radhakrishnan SV, Hadidi SA, Szabo A, D’Souza A, Zangari M, Rhee FV, Chhabra S, Schinke C. . Corneal Toxicity Limits Clinical Efficacy of Belantamab mafodotin: Multi-institutional Real-Life Experience. Am J Hematol 97(12):8451-E453, 2022. e-Pub 2022. PMID: 36097868.
46. Mohan M, Nagavally S, Nirav N Shah N, Michaelis L, Chhabra S, D’Souza A, Abedin S, Runaas L, Guru Murthy GS, Longo W, Ledeboer N, Mehdi Hamadani M, Dhakal B, Hari P, Fenske TS. Shorter Interval between Treatment and COVID Immunization is Associated with Poor Seroconversion in Patients with Hematological Malignancies. Clin Lymphoma Myeloma Leuk 22(7):e495-e497, 2022. e-Pub 2022. PMID: 8767926.
47. Dweik A, Dweik H, Mian H, Mohan M, Schinke C, Hadidi SA. Gender Disparities in Multiple Myeloma Publications. EJHaem 3(3):966-969, 2022. e-Pub 2022. PMID: 9422002.
48. Mohan :M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D’Souza A, Hari P. Risk of infections with BCMA-directed Immunotherapy in Multiple Myeloma. Blood Adv 6(8):2466-2470, 2022. e-Pub 2022. PMID: 9043928.
49. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Hadidi SA, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, Rhee FV, Usmani SZ, D’Souza A, Orlowski RZ, Schinke C. Clinical Efficacy of Sequencing CD38 targeting monoclonal antibodies in Relapsed Refractory Multiple Myeloma: A multi-institutional real-world experience. Am J Hematol 97(7):e276-e280, 2022. e-Pub 2022. PMID: 10476149.
50. Mohan M, Bailey C, Hill K, Spencer H, Kottarathara M, Parikh R, Hoque S, Amani E, Mitma A, Mathur P, Tricot G, Thanendrarajan S, Zangari M, Rhee FV, Schinke C. Feasibility of outpatient stem cell transplantation in multiple myeloma and risk factors that predispose for hospital admission. J Clin Med 11(6):1640, 2022. e-Pub 2022. PMID: 35329966.
51. Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Alapat D, Thanendrarajan S, Hadidi SA, Zangari M, Rhee FV, Schinke C. Tandem Autologous Stem Cell Transplantation in Patients with Persistent Bone Marrow Minimal Residual Disease Post First Transplantation in Multiple Myeloma. Am J Hematol, 2022. e-Pub 2022. PMID: 35285981.
52. Dong J, Garacci Z, Buradagunta CS, Mohan M, D'Souza A, Cunningham A, Janz S, Dhakal B, Hari AP. Black Patients with Multiple Myeloma Have Better Survival than White Patients When Treated Equally: A Matched Cohort Study. Blood Cancer J, 2022. e-Pub 2022. PMID: 35210395.
53. Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah N, Fenske T, Abedin S, Runaas L, D’Souza A, Chhabra S, Dhakal B, Hamadani M. Effectiveness of mRNA-based SARS-CoV-2 vaccine booster among non-seroconverting hematopoietic cell transplantation, CAR T-cell and BiTE recipients. Cancer Cell 40(4):340-342, 2022. e-Pub 2022. PMID: 35202585.
54. Kendrick S, Yarlagadda N, Atwal D, Pandey Y, Roy A, Parikh R, Lopez J, Thanendrarajan S, Schinke C, Alapat D, Sawyer J, van Rhee ETF, Zangari M. Clinical Implications of Loss of Bone Marrow Minimal Residual Disease (MRD) Negativity in Multiple Myeloma. Blood Adv 6(3):808-817, 2022. e-Pub 2022. PMID: 34807986.
55. Hammons LR, Szabo A, Janardan A, Dhakal B, Chhabra S, D'Souza A, Mohan M. Kinetics of Humoral Immunodeficiency with Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma. JAMA Netw Open, 2022. e-Pub 2022. PMID: 36306135.
56. Mohan M, Szabo A, Dhakal B, Chhabra S, Hari P, D’Souza A. Long term follow up of Newly Diagnosed Multiple Myeloma (NDMM) patients treated with Pembrolizumab consolidation post autologous stem cell transplantation (ASCT). Leuk Res(109):106648, 2021. e-Pub 2021. PMID: 34182226.
57. Abdallah A, Mohyuddin GR, Ahmed N, Mohan M, Cui W, Shune L, Mahmoudjafari Z, McGuirk J, Ganguly S, Atrash S. Outcomes of VDPACE with an Immunomodulatory Agent (IMiD) as a Salvage Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD). EJHaem 2(4):757-764, 2021. e-Pub 2021. PMID: 9175829.
58. Yarlagadda N, Gundarlapalli S, Sharma S, Suelzer E, Abid MB, Abdallah A, Schinke C, Atrash S, Mohan M. Infectious Complications with CD-38 Targeting Monoclonal Antibody Based Therapies in Multiple Myeloma: A Meta-analysis of Randomized Control Trials. Leuk Res, 2021. e-Pub 2021.
59. Pennipede D, Mohyuddin GR, Hawkins R, Ganguly S, Shune L, Ahmed N, Mohan M, Cui W, Mahmoudjafari Z, McGuirk J, Atrash S, Abdallah A. Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-class Relapsed/Refractory Multiple Myeloma (RRMM). A Single Institution Experience. Eur J Haematol 107(6):602-608, 2021. e-Pub 2021. PMID: 34378251.
60. Mohan M, Meek JC, Meek ME, Broadwater R, Alapat D, Rhee FV. Combinatorial Treatment for Unresectable Unicentric Castleman Disease. Eur J Haematol 107(4):484-488, 2021. e-Pub 2021. PMID: 34242421.
61. Mohan :M, Szabo A, Yarlagadda N, Gundarlapalli S, Thanendrarajan S, Schinke C, Alapat D, Rhee FV, Zangari M. Persistent Bone Marrow Minimal Residual Disease in Multiple Myeloma is associated with Dismal Outcome. Am J Hematol 96(9):e341-e344, 2021. e-Pub 2021. PMID: 34050985.
62. Mohan M, Tian E, Desai S, Rhee FV, Thanendrarajan S, Schinke C, Suva LJ, Sharma S, Kumar M, Milad M, Kendrick S, Zangari M. Bone remineralization Of Lytic Lesions in Multiple Myeloma--The Arkansas Experience. Bone(146):115876, 2021. e-Pub 2021. PMID: 8627246.
63. Mohan M, Maatman TC, Schinke C. The Role of Monoclonal Antibodies in the Era of Bi-specifics antibodies and CAR-T cell therapy in Multiple Myeloma. Cancers (Basel) 13(18):4909, 2021. e-Pub 2021. PMID: 34638393.
64. Kamaraju S, Mohan M, Zaharova S, Gor D, Wallace B, McGraw J, Lokken J, Tierney J, Weil E, Fatunde O, Brown S. Interactions between Cardiology and Oncology Drugs in Precision Cardio-Oncology. Clin Sci (Lond) 135(11):1333-1351, 2021. e-Pub 2021. PMID: 34076246.
65. Yarlagadda :L, Gunarlapalli S, Parikh R, Landes R, Kottarathara M, Ogunsesan Y, Hoque S, Mitma A, Bailey C, Hill K, Thanendrarajan S, Graziutti M, Mohan M, Zangari M, Guido Tricot FVR, Schinke C. Salvage Autologous Stem Cell Transplantation in Daratumumab refractory Multiple Myeloma. Cancers (Basel) 13(16):4019, 2021. e-Pub 2021. PMID: 34439174.
66. Thapa B, Ahmed G, Mohan M, Shponka V, Hari P. Pulmonary Lymphangitic Spread of Multiple Myeloma as Early Relapse Post Autologous Stem Cell Transplantation. Case Rep Hematol:5590975, 2021. e-Pub 2021. PMID: 8041536.
67. Mohan M, Yarlagadda N, Szabo A, Oviedo SP, Schinke C. Clinical Characteristics of Testicular Extramedullary Involvement in Multiple Myeloma. Am J Hematol 96(3):e77-e81, 2020. e-Pub 2020. PMID: 33338289.
68. Dhakal B, D’Souza A, Kleman A, Chhabra S, Mohan M. Salvage Second Transplantation in Relapsed Multiple Myeloma. Leukemia 35(4):1214-1217, 2020. e-Pub 2020. PMID: 32747684.
69. Schinke C, Boyle EM, Ashby C, Wang Y, Lyzogubov V, Wardell C, Qu P, Hoering A, Deshpande S, Ryan K, Thanendrarajan S, Mohan M, Yarlagadda N, Khan M, Choudhury SR, Zangari M, Rhee FV, Davies F, Barlogie B, Morgan G, Walker BA. Genomic Analysis of Primary Plasma Cell Leukemia reveals complex Structural Alterations and High- Risk Mutational Patterns. Blood Cancer J 10(6):70, 2020. e-Pub 2020. PMID: 32555163.
70. Lopez J, Raval M, Mohan M. Refractory Hypercalcemia in Multiple Myeloma: An Infectious Etiology. James Lopez, MD. Transpl Infect Dis 22(5):e13354, 2020. e-Pub 2020. PMID: 32500970.
71. Udaondo Z, Jenjaroenpun P, Wongsurawat T, Meyers E, Anderson C, Lopez J, Mohan M, Tytarenko R, Walker B, Ussery D, Kothari A, Ju S. Two Cases of Vancomycin Resistant Enterococcus faecium Bacteremia with Development of Daptomycin Resistant Phenotype and its Detection Using Oxford Nanopore Sequencing. Case Reports Hepatol 7(6), 2020. e-Pub 2020. PMID: 32550237.
72. Jenjaroenpun P, Wongsurawat T, Udaondo Z, Anderson C, Lopez J, Mohan M, Tytarenko R, Walker B, Nookaew I, Ussery D, Kothari A, Jun S. Complete Genome Sequences of Four Isolates of Vancomycin-Resistant Enterococcus faecium with vanA Gene from Two Patients with Prolonged Bacteremia. Microbiol Res 9(6):e01380-19, 2020. e-Pub 2020. PMID: 32029568.
73. Mohan M, Weinhold N, Rhee FV, Schinke C, Thanedrarajan S, Rasche L, Sawyer J, Tian E, Davies F, Morgan G, Zangari M. Daratumamab in High-Risk Relapse/Refractory Myeloma Patients: Effect of 1q21 Duplication and GEP70 Status. Br J Haematol 189(1):67-71, 2019. e-Pub 2019. PMID: 31820442.
74. Lopez J, Yarlagadda N, Gheith Z, Mohan M, Sasapu A. Nivolumab-Induced Immune-Mediated Neurotoxicity in Hodgkin’s Lymphoma. Proc (Bayl Univ Med Cent) 33(1):59-61, 2019. e-Pub 2019. PMID: 6988700.
75. Udaondo Z, Wongsurawat T, Jenjaroenpun P, Anderson C, Lopez J, Mohan M, Tytarenko R, Walker B, Nookaew I, Ussery D, Kothari A, Jun S. : Draft Genome Sequences of 48 Vancomycin-Resistant Enterococcus faecium Strains Isolated from Inpatients with Bacteremia and Urinary Tract Infection. Microbiol Res 8(15):e00222-19, 2019. e-Pub 2019. PMID: 6460033.
76. Mohan M, Susanibar-Adaniya S, Buros A, Rico Crescencio JC, Burgess MJ, Lusardi K, Davies F, Morgan G, Vanrhee F, Zangari M, Schinke C, Thanendrarajan S, Kothari A. Bacteremias Following Autologous Stem Cell Transplantation for Multiple Myeloma: Risk Factors and Outcomes. Transpl Infect Dis 21(2):e13052, 2019. e-Pub 2019.
77. Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar-Adaniya S, Kamimoto JJ, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, Rhee FV, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol 92(8):739-745, 2018. e-Pub 2018. PMID: 28383130.
78. Hildebrandt GC, Berno T, Gurule A, Mohan M, Yoon D, Salama M, Zangari M. Effect of low dose bortezomib on bone formation in smouldering multiple myeloma. Blood 122(21):3204, 2018. e-Pub 2018.
79. Schinke C, Hoering A, Wang H, Carlton V, Thanendrarajan S, Deshpande S, Patel P, Molnar G, Susanibar-Adaniya S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Kamimoto JJ, Grazziutti M, Rhee FV, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologia (Budap) 102(8):e313-e316, 2017. e-Pub 2017. PMID: 28522572.
80. Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, Rhee FV, Davies FE, Morgan GJ, Zangari M. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients with Multiple. J Bone Miner Res 32(6):1261-1266, 2017. e-Pub 2017. PMID: 28240368.
81. Mohan M, Matin A, Davies FE. Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer Manag Res, 2017. e-Pub 2017. PMID: 28280389.
82. Mohan M, Fogel B, Eluvathingal T, Schinke C, Kothari A. Gastrointestinal histoplasmosis in a patient after autologous stem cell transplant for multiple myeloma. Transpl Infect Dis 8(6):9939-941, 2016. e-Pub 2016. PMID: 27696648.
83. Mohan M, Shalin SC, Kothari A, Rico JC, Caradine K, Burgess. Lasiodiplodia species fungal osteomyelitis in a multiple myeloma patient. Transpl Infect Dis, 2016. e-Pub 2016. PMID: 27391908.
84. Mohan M, Gokden M, Schinke C. A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma. Am J Case Rep:173-6, 2016. e-Pub 2016.
85. Heuck CJ, Jethava Y, Khan R, van Rhee F, Zangari M, Chavan S, Robbins K, Miller SE, Matin A, Mohan M, Ali SM, Stephens PJ, Ross JS, Miller VA, Davies F, Barlogie B, Morgan G. Inhibiting MEK in MAPK pathway-activated myeloma:976-80, 2015. e-Pub 2015. PMID: 26228812.
86. Mohan M, Oekelen OV, Akhtar OS, Cohen A, Parekh S. Charting the Course: Sequencing Immunotherapy for Myeloma 44(3):E432204. PMID: 38875506.
87. Kamaraju S, Mohan M, Wright T, Charlson J, Wiger W, Kwarteng J, Rezazadeh A, Hammons L, Power S. Addressing the disparities and the factors related to prolonged inpatient length of stay for solid tumor oncology patients during the COVID-19 pandemic: A narrative review. Journal of Radiology and Oncology.
88. Gundroo HM, Nasrollahi E, Alford B, Dhakal B, Narra R, Mohan M, D’Souza A, Mhaskar R, Salim Akhtar AO. Outcomes Of Older and Frail Patients with Relapsed/Refractory Multiple Myeloma Treated with Bispecific Antibodies: A Systematic Review and Meta-Analysis. Blood Adv 9(15):4016-4022. PMID: 40315372.
89. Kasomva K, Murray J, Pulakanti K, Nickerson A, Pulakanti K, Stelloh C, Ray A, Yadav K, Narra R, Pasquini M, D’Souza A, Mohan M, Akhtar O, Ruzicka M, Sun F, Parashar D, Janz S, Rao S, Dhakal B. Immune Restoration in Long-Term Myeloma Survival Revealed by Single-Cell RNA-Sequencing. Leukemia.
90. Mian H, Faisal MS, Chen T, Brazauskas R, Oloyede T, Ahmed N, Afrough A, Anderson L, Banerjee R, Berdeja J, Bidikian A, Devos J, Dhakal B, Dias A, Dima D, Efebera Y, Gowda L, Hansen D, Hashmi H, Landau H, Lekakis L, Mirza A, Narra R, Patel K, Rosko A, Schroeder M, Sidana S, Usmani S, Pasquini M, Nishihori T, Akhtar OS, Mohan M. Efficacy and Safety of Frail Adults Treated with Ciltacabtagene Autoleucel in the Real World: A CIBMTR analysis.
91. Shah MR, Bag A, Shrestha A, Ogunsesan Y, Trikannad A, Vellanki S, Muttineni S, Cheema H, Naqvil S, Dronavalli S, AlHadidi S, Thanendrarjan S, Zangari M, Rhee FV, Szabo A, Chakraborty R, Mohan M, Schinke C. The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory Multiple Myeloma.
92. Semenkovich NP, George A, Bag A, Shah M, Radhakrishnan SV, Ogunsesan Y, Pasvolsky O, Chakraborty R, Schinke C, Szabo A, Mohan M. Machine learning models to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma.
93. Mohan M, Chari A, de Donk NWV. How To Prevent Infections in Patients Receiving T-Cell Directed Therapies for Multiple Myeloma.
94. Mohan M, Hari P, Dhakal B. Multiple Myeloma–Time for a second major paradigm shift. JCO Oncol Pract 17(7):405.

Other Articles

1. Mohan M, Janz S, Brazauskas R, Dwinell MB, Teng BQ, Yun G, Dong J, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, Flynn KE, D’Souza A Change in cytokine levels at one-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy: a correlative subset analysis of BMT CTN 0702. Bone Marrow Transplant 58(8):953-955, 2023.

Abstracts

1. Mohan M, Szabo A, Narra RK, Skoog C, Goff A, Dhakal B, Akhtar O, Pasquini M, Radhakrishnan S, Rao S, Malarkannan S, Schinke C, Rasche L, D'Souza A. Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma. 67th American Society of Hematology, 2025.
2. Noveihed A, Hadidi SA, Mohan M, Shah MR. Bispecific Antibody Therapy in CNS Myeloma: Insights from a Multicenter Retrospective Study. American Society of Clinical Oncology, 2025.
3. Banerjee R, Mohan M, Shah B, Prince T, Gautam N, Conroy B, Beebee E, Hughes D, Nador G, Hlavacek P, Sandin R, Li B, Meche A, Kim CH, Cruz IP, Sumaya M, DiBonaventura M. Healthcare Resource Utilization and Costs Associated with Elranatamab Initiation in Multiple Myeloma: the ALTITUDE-1 Study. ISPOR, 2025.
4. Mohan M, Kortüm M, Baljević M, Farrell J, Zhuleku E, McDonald K, Meche A, Demers A, Ashman O, Hughes D, Nador G, Rückert M, Theurich S. Treatment Patterns and Effectiveness In An Anti-Cd38 And Lenalidomide Pretreated RRMM Population: Data From Two Real-World Datasets. 30th European Hematology Association Congress, 2025.
5. Banerjee R, Mohan M, Prince P, Gautam N, Conroy B, Beebe E, Hughes D, Nador G, Hlavacek P, Sandin R, Li B, Meche A, Kim CH, Cruz IP, Sumaya M, Dibonaventura M. . Systemic review and Meta-analysis of Safety and Efficacy of Bispecific antibodies among Older Adults with Multiple Myeloma. 30th European Hematology Association Congress, 2025.
6. Hashmi H, Mohan M, Geyer S, Pederson L, Schumacher P, Gater P, James S, Semmel E, Cleaves T, Rosenberg A, Rubinstein S, D'Souza A, Cook J, Schroeder M, Sperling A, Zonder J, Nooka A, Martin T, Bhutani M, Richard S, Usmani S. 89. Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis. 67th American Society of Hematology, 2025.
7. Dhakal B, Hintzke M, Akhtar O, Mammadova J, Kassim A, Pasquini M, Mohan M, Narra RK, Radhakrishnan S, Sun F, D'Souza A, Albitar M, Dholaria B. 88. Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights. 67 67th American Society of Hematology, 2025.
8. Kasomva K, Pulakanti K, Murray J, Yadav K, Narra R, Pasquini M, D'Souza A, Mohan M, Akhtar O, Parashar D, Sun F, Janz S, Dhakal B, Rao S. . Immune restoration in long-term myeloma survival revealed by single-cell RNA-sequencing. 67th American Society of Hematology, 2025.
9. Janardan A, Jumin P, Thorgerson A, Narra RK, Akhtar O, Radhakrishnan S, Pasquini M, Dhakal B, D'Souza A, Mohan M. Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses. 67th American Society of Hematology Meeting, 2025.
10. Mohan M. Evaluating Outcomes with Standard-of-Care Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. International Myeloma Society, 2025.
11. Mohan M, Banerjee R, Shah B, Pajerowski W, Cantu C, Meiseles H, Beebe E, Hughes D, Nador G, Hlavacek P, Sandin R, Li B, Meche A, Kim CH, Cruz IP, Sumaya M, DiBonaventura M. Real-World Treatment Patterns Associated With Elranatamab Among Patients With Relapsed/Refractory Multiple Myeloma: The ALTITUDE-2 Study. International Myeloma Society, 2025.
12. Vega G, Morillo D, Riedhammer C, Bag A, Julian K, Gomis NT, Bermudez MA, Shah MR, Mohyuddin GR, Dhakal B, Lentzsch S, Rasche L, Schinke C, Anita, D’Souza, Szabo A, Chakraborty R, Mohan M. Sustained Remission After Limited Duration of Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma. International Myeloma Society, 2025.
13. Su M, Kaur G, Mohan M, Anderson L, Banerjee R, Gong Z, Khan A. Early treatment with daratumumab in patients with multiple myeloma and renal failure: A real-world analysis. International Myeloma Society, 2025.
14. Semenkovich N, George A, Bag A, Shah M, Radhakrishnan S, Dhakal B, Hadidi SA, Chakraborty R, Schinke C, D'Souza A, Szabo A, Mohan M. A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma. American Society of Hematology, 2025.
15. Mian H, Faisal MS, Chen T, Brazauskas R, Oloyede T, Ahmed N, Afrough A, Anderson L, Banerjee R, Berdeja J, Bidikian A, Devos J, Dhakal B, Dias A, Dima D, Efebera Y, Gowda L, Hansen D, Hashmi H, Landau H, Lekakis L, Mirza A, Narra R, Patel K, Rosko A, Schroeder M, Sidana S, Usmani S, Pasquini M, Akhtar O, Nishihori T, Mohan M. Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis. 67th American Society of Hematology, 2025.
16. Dhakal B, Slade M, Mohamed M, Schroeder M, Narra RK, Akhtar O, Bansal H, Acevedo-Calado M, Pasvolsky O, Gaballa M, Becnel M, Weber D, Patel K, Thomas S, Ye JC, Mohan M, Pasquini M, Sun F, Stockerl-Goldstein K, D'Souza A, Vij R, Albitar M, Orlowski R, Lee H. Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM). 67th American Society of Hematology, 2025.
17. Hydren J, Jensen R, Hurtado Martinez JA, Ahlstrom J, Barnes M, Costello C, Kaur G, Mohan M, Cottini F, Sborov D, Kumar S, Raje N, Moreau P, Deshpande M, Gupta-Werner N, Blanc TL, Fowler J, Banerjee R. Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey. 67th American Society of Hematology, 2025.
18. Mohan M. Real-World Comparison of Anti-BCMA CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma: a CIBMTR Study. International Myeloma Society, 2025.
19. Yohay S, Kim S, Lin M, Oloyede T, Narra R, Radhakrishnan S, Mohan M, Dhakal B, Pasquini M, D'Souza A, Akhtar O. . High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies. 67th American Society of Hematology, 2025.
20. Kent J, Jin Y, Skoog C, Goff A, Akhtar OS, Narra R, Hadidi SA, Thanendrarajan S, Zangari M, Rhee FV, Pasquini M, Sreedharanunni S, Dhakal B, D’Souza A, Korde N, Szabo A, Schinke C, Mohan M. Performance of Bone Marrow Minimal Residual Disease (MRD) Detection by Next Generation Sequencing for Multiple Myeloma. American Society of Clinical Oncology, 2025.
21. Leleu X, Chung A, Raje N, Mohan M, Benjamin R, Sperling A, Anderson L, Dhodapkar M, Richard S, Kivovich V, Johnston S, Wu F, Basudhar D, Thompson E, Dhanda D, Eliason L, Tran S, Chaudhry M, Alsina M. Idecabtagene Vicleucel (Ide-Cel) In Patients (Pts) With Clinical High-Risk Early Relapse Multiple Myeloma (Mm) Without Frontline Autologous Stem Cell Transplantation (ASCT): Karmma-2 Cohort 2b. European Hematology Association, 2024.
22. Mohan M. Outcomes of Frail Patients Receiving High-Dose Chemotherapy/Autologous stem Cell Transplantation for Multiple Myeloma. European Society of Blood and Marrow Transplantation, 2024.
23. Furqan F, Bhatlapenumarthi V, Fenske TS, Longo W, Shah NN, D’Souza A, Pasquini MC, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Dhakal B, Hamadani M. Outpatient Administration of Commercial antiCD19 and antiBCMA Chimeric Antigen Receptor-modified T-cell (CAR-T) Therapies Using a Strategy of No Remote Monitoring and Early Cytokine Release Syndrome (CRS) Intervention. Tandem Meetings, Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, 2024.
24. Cheruvalath H, Clennon A, Szabo A, Bhatlapenumarthi V, Patwari A, Bhutani D, Shrestha A, Thanendrarajan S, Dhakal B, Zangari M, Trikannad A, Vellanki S, Al-Hadidi S, Lentzsch S, Rhee FV, Shah MR, Bag A, D’Souza A, Chakraborty R, Shah N, Schinke C, Mohan M. . Effects of Early Use of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-institutional study. 66th American Society of Hematology, 2024.
25. Vandenboom H, Szabo A, Akhtar O, Narra R, Mohan M, D’Souza A, Pasquini M, Dhakal B. CAR-T vs. bispecific antibody against B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma: A systematic review and meta-analysis. 66th American Society of Hematology, 2024.
26. Kasomva K, Pulakanti K, Murray J, Narra R, Pasquini M, D’Souza A, Mohan M, Akhtar O, Parashar D, Janz S, Dhakal B, Rao S. Single-cell RNA analysis reveals a distinct molecular profile pattern in Long-Term Survival Multiple Myeloma patients, 2024.
27. Dhakal B, Slade M, Narra R, Mohamed M, Akhtar O, Bansel H, Acevedo-Calado MJ, Pasvolsky O, Gaballa MR, Becnel MR, Weber DM, Patel KK, Thomas SK, Ye C, Kuhr F, Dong B, Powell S, Bui T, Mohan M, Pasquini M, Halyna Knysh AD, Maher Albita RZO, Lee HC. . Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma. 66th American Society of Hematology, 2024.
28. Chunara F, Shah M, Shah N, Kent J, Mohyuddin GR, Radhakrishnan SV, Kaur G, Rajshekhar Chakraborty MD, Banerjee R, Rasche L, Schinke C, D’Souza A, Szabo A, Mohan M. . Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience From 609 Patients. 66th American Society of Hematology, 2024.
29. Yadav K, Patel T, Bachu R, Esselmann J, Rein LE, Szabo A, Janardan A, Annyapu E, Skoog C, Goff A, Akhtar OS, Hadidi SA, Thanendrarajan S, Zangari M, Shah N, Rhee FV, Hamadani M, Dhakal B, D’Souza A, Mohan M, Schinke C. Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-cell Therapy for Multiple Myeloma (MM. 66th American Society of Hematology, 2024.
30. Tan Aldecoa KA, Loh KP, Lee Y, Arsene C, Krishnamoorthy G, Mohan M. Comparison of Healthcare Utilization in Patients Undergoing CAR T-Cell Therapy for Multiple Myeloma and Lymphoma. 66th American Society of Hematology, 2024.
31. Shrestha A, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, MD SL, Rhee FV, Bag A, D’Souza A, Chakraborty R, Shah N, Shah MR, Mohan M, Schinke C. The efficacy of Teclistamab in multiple myeloma patients with secondary plasma cell leukemia. 66th American Society of Hematology, 2024.
32. Balev M, Shah N, Shah MR, D’Souza A, Patwari A, Szabo A, Dhakal B, Cheruvalath H, Forsberg M, Bhatlapenumarthi V, Al-Hadidi S, Lentzsch S, Bhutani D, Chakraborty R, Schinke C, Mohan M. Efficacy and safety of teclistamab in relapsed refractory multiple myeloma: long-term follow-up from a real world multi-institutional cohort. 66th American Society of Hematology, 2024.
33. Khan AM, Gong Z, Prasad T, Banerjee R, Mohan M, Kaur G. Anti-CD38 Monoclonal Antibodies in Multiple Myeloma with Renal Failure: A Real-World Analysis. 66th American Society of Hematology, 2024.
34. Akthar O, Szabo A, Monge J, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Patel T, Shrestha A, Al-Hadidi S, Cooper D, Lentzsch S, Rhee FV, Shah M, D’Souza A, Schinke C, Chakraborty R, Shah N, Mohan M. . Immune Prognostic Score Predicts Risk of Infection and Survival Outcomes in Patients with Relapsed Multiple Myeloma Treated with Bispecific Antibodies. American Society of Clinical Oncology, 2024.
35. Patwari A, Patel T, Bachu R, Esselmann J, Rein LE, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Thanendrarajan S, Zangari M, Rhee FV, Dhakal B, D’Souza A, Mohan M, Schinke C. The Effect of Stem Cell Infusion on Immune Effector Cell Associated Hematotoxicity with BCMA CAR T In Multiple Myeloma. Clinical and Translational Science Institute and Milwaukee Regional, 2023.
36. Mohan M, Monge J, Shah N, Danny Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Anannya Patwari MD, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, Rhee FV, D’Souza A, Szabo A, Schinke C, Chakraborty R. Teclistamab in Relapsed Refractory Multiple Myeloma: A Multi-Institutional Real-World Study. American Society of Hematology, 2023.
37. Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, Radhakrishnan SV, Chakraborty R, Schinke C, D’Souza A, Mohan M. Adverse Effects and Non-relapse Mortality Of Novel Therapeutics In Multiple Myeloma FAERS Database Study. American Society of Hematology, 2023.
38. Rao S, Pulakanti K, Meyer A, Ray A, Carlson K, Knight J, D’Souza A, Mohan M, Narra R, Pasquini M, Hari P, Janz S, Dhakal AB. Single Cell Analysis in Long-Term Survivors of Multiple Myeloma Reveals a Novel Cytotoxic Response, 2023.
39. Lin M, Szabo A, Pezzin L, Dong J, Dhakal B, Mohan M, Narra R, Pasquini M, D’Souza A. Does Socioeconomic Deprivation Have an Impact on Light Chain (AL) Amyloidosis Disease and Outcomes?. American Society of Hematology, 2023.
40. Wu JF, Estrada-Merly N, Dhakal B, Mohan M, Narra RK, Pasquini MC, Esselmann J, Goff AD, Skoog CE, D’Souza A. . Racial disparities in autologous stem cell transplant utilization in multiple myeloma persist despite referral to a transplant center. American Society of Hematology Meeting, 2023.
41. Dhakal B, Mohan M, Narra R, Palen K, Szabo A, Kearl T, Gayathri R, Bal S, Johnson B, Pasquini M, D’Souza A, Costa L. Dual targeting of SLAMF-7 and CD38 in Mulitple Myeloma (MM): A phase II study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and/or Refractory MM (RRMM). American Society of Hematology, 2023.
42. Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Sborov D, Mohan M, Mian H, Chakraborty R, Mohyuddin GR. Gain1q in Myeloma Randomized Clinical Trials- How is it reported and how does it impact outcomes: A Systematic Review. American Society of Hematology, 2023.
43. Schjesvold F, Spencer A, Cohen YC, Ocio EM, Pardo JL, Cafro AM, Callander NS, Kaufman J, Mohan M, Wermke M, Doki N, Kan R, Kulec K, Trabucco G, Ye S, Sechaud R, Quadt C, Chawla R, Raab MS. . Initial Results From a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination With WHG626, a Gamma-Secretase Inhibitor, in Patients With Relapsed and/or Refractory Multiple Myeloma. American Society of Hematology, 2023.
44. Hammons L, Haider S, Pasquini M, Chhabra S, Radhakrishnan SV, Zamora A, Mohan M, Dong J, Janz S, D’Souza A, Hari P, Dhakal B. Chimeric antigen receptor-T (CAR-T) cell therapy targeting BCMA in patients with prior allogeneic transplantation (allo-HCT) in relapsed and/or refractory multiple myeloma (RRMM). American Society of Hematology, 2022.
45. Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Thanendrarajan S, Hadidi SA, Zangari M, Rhee FV, Schnicke C. Tandem Autologous Stem Cell Transplantation in Patients with Persistent Bone Marrow Minimal Residual Disease Post First Transplantation in Multiple Myeloma. Transplantation And Cellular Therapy Meeting, 2022.
46. Hammons LR, Szabo A, Dhakal B, Radhakrishnan SV, Chhabra S, D’Souza A, Mohan M. Kinetics of Humoral Immunodeficiency with Bispecific Antibody Therapy in Multiple Myeloma. ASCO, 2022.
47. Mailankody S, Matous JV, Liedtke M, Sidana S, Oluwole OO, Meera, M, Cruz JC, Nath R, Anwer F, Rossi, A, Htut M, Malik SA, Ghatta S, Dillon M, Ying W, Navale L, Karski EE, Balakumaran A, Kumar SK. Verhagen, S Thalji, M Mohan, A Shreenivas, CN Clarke, KK Christians, S Tsai, DB Evans, A Szabo, AN Kothari. American Society of Hematology, 2022.
48. Jain J, Khasawneh G, Hashmi H, Mohan M, Mahmoudjafari Z, Cu W, McGuirk J, Shune L, Nausheen, Ahmed, Abdallah A, Shebli A. Daratumumab, pomalidomide and dexamethasone (DPd) versus Daratumumab, velcade and dexamethasone (DVd) in previously treated daratumumab naïve relapsed refractory Multiple Myeloma patients. American Society of Hematology Meeting, 2022.
49. Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardhan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D’Souza A, Zangari M, Rhee FV, Mohan M. Current wait time for patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR T therapy. American Society of Hematology, 2022.
50. Mohan M, Verhagen N, Shreenivas A, Radhakrishnan SV, Dhakal B, Chhabra S, Thompson M, Pasquini M, D’Souza A, Hamadani M, Szabo A, Kothari A. . Blood and Marrow Transplant Within Four Weeks of SARS-CoV-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study. American Society of Hematology, 2022.
51. Janardan A, Hammons L, Szabo A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Narra R, Hadidi S, Radhakrishnan SV, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Rhee PhD FV, D’Souza A, Chakraborty R, Schinke C, Mohan M. Changing Spectrum of Infection with BCMA and GPRC5D Targeting Bispecific Antibody Therapy in Patients with Relapsed Refractory Multiple Myeloma (RRMM). Medical College of Wisconsin 10th Annual Department of Medicine Research Meet, 2022.
52. Kerschner A, Hodge A, Williams A, Sheean P, Jensik K, Visotcky A, Hari P, Mohan M, Chhabra S, D'Souza A, Stolley M. Exploring Interest in and Feasibility of a Lifestyle Intervention for Multiple Myeloma Patients. American Society of Hematology, 2021.
53. Chung DJ, Shah N, Stroopinsky D, Juan WU, Bisharat L, Callander NS, Logan BR, Anderson KC, Chodon T, Mohan M, Devine S, Efebera YA, Geller N, Hematti P, Holmberg LA, Howard A, Johnson B, Lazarus HM, Malek E, McCarthy PL, McKenna DH, Mendizabal AM, Munshi NC, O'Donnell L, Rapoport AP, Nooka AK, Reese J, Soiffer RJ, Uhl L, Cheloni G, Karagkouni D, Vlachos I, Young JW, Rosenblatt J, Waller EK, Pasquini MC, Avigan D. Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed by Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401). American Society of Hematology, 2021.
54. Dong J, Garacci Z, Buradagunta CS, Mohan M, D'Souza A, Cunningham A, Janz S, Dhakal B, Hari P. . Characteristics Associated with Disparities in Survival between Hispanic and Non-Hispanic White Patients with Multiple Myeloma: A Matched Cohort Study. American Society of Hematology, 2021.
55. Mohan M, Gong Z, Kendrick S, Thanendrarajan S, Schinke C, Alapat D, Tricot G, Zhan F, Rhee FV, Sawyer J, Tian E, Zangari M. Concomitant deletion of short arm (del 1p) and amplification or gain (1q21) of chromosome 1 by Interphase fluorescence in situ hybridization (iFISH) is associated with poor clinical outcome. American Society of Hematology, 2021.
56. Yarlagadda N, Mohan M, Atrash S, Gundarlapalli S, Hoque S, Kakadia S, Thanendrarajan S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, Zhan F, Rhee FV, Zangari M. Eight Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance. American Society of Hematology, 2021.
57. Mohan M, Nagavally S, Dhakal B, D’Souza A, Chhabra S, Hari P. . Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma (RRMM): Is there an excess risk of infection?. American Society of Hematology, 2021.
58. Abdallah A, Mahmoudjafari Z, Mohan M, McGuirk J, Remker C, Foss M, Karloff E, Fitch H, Mohyuddin GR, Atrash S. Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination. American Society of Hematology, 2021.
59. Abdallah A, Mahmoudjafari Z, Ahmed N, Mohan M, Cui W, Shune L, McGuirk J, Mohyuddin GR, Atrash S. Clinical efficacy of re-treatment of daratumumab-based therapy in relapsed/refractory multiple myeloma who are daratumumab refractory. American Society of Hematology, 2021.
60. Atieh T, Atrash S, Ahmed N, Mohan M, Cui W, Shune L, Mahmoudjafari Z, Quick J, Wishna A, Riffel J, McGuirk J, Mohyuddin GR, Abdallah A. Belantamab in combination with dexamethasone in patients with triple-class Relapsed/Refractory RRMM in the real world. American Society of Hematology, 2021.
61. Dhakal B, Felizardo T, D’Souza A, Chhabra S, Keaton T, Mohan M, Park H, Fowler DH, Hari P. Phase 2 trial of polyclonal Temsirolimus- resistant autologous Th1/Tc1 cells (RAPA 201) for Relapsed Refractory Multiple Myeloma. American Society of Hematology, 2021.
62. Lonial S, Tarantolo S, Boccia R, Yimer HA, Levy MY, Abonour R, Mohan M, Roy V, Larsen JT, Girnius S, Rosenbaum C, Nadeem O, Berg D, Chao B, Berger AJ, Nakamura A, Zhang Y, Song K, Ward C, Proscurshim I, Kumar SK. Phase 1b/2 Study of the First-in-class SUMO-activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-class Refractory Multiple Myeloma. American Society of Hematology, 2021.
63. Yarlagadda L, Gunarlapalli S, Parikh R, Kottarathara M, Ogunsesan Y, Hoque S, Mitma A, Bailey C, Hill K, Thanendrarajan S, Graziutti M, Mohan M, Zangari M, Guido Tricot FVR, Schinke C. . The role of Salvage Autologous Stem Cell Transplantation in Penta-refractory Multiple Myeloma. American Society of Clinical Oncology, 2021.
64. Mohan M, Kendrick S, Pandey Y, Parikh R, Farmer P, Kottarathara M, Hoque S, Mitma A, Thanendrarajan S, Schinke C, Tricot G, Zangari M, Rhee FV. Late Relapsing Multiple Myeloma ≥ 10 years after Treatment on Total Therapy Protocols. American Society of Hematology, 2020.
65. Larsen K, Mohan M, Bailey C, Hill K, Spencer H, Kottarathara M, Parikh R, Hoque S, Amani E, Mitma A, Mathur P, Tricot G, Thanendrarajan S, Zangari M, Rhee FV, Schinke C. Feasibility of outpatient stem cell transplantation in multiple myeloma and risk factors that predispose for hospital admission. American Society of Hematology, 2020.
66. Mohan M, Yarlagadda N, Atwal D, Pandey Y, Roy A, Parikh R, Lopez J, Thanendrarajan S, Schinke C, Alapat D, Rhee FV, Kendrick S, Zangari M. Clinical Implications of Loss of Minimal Residual Disease (MRD) Negativity in Multiple Myeloma. American Society of Clinical Oncology, 2020.
67. Udaondo Z, Jenjaroenpun P, Wongsurawat T, Walker B, Anderson C, Lopez J, Mohan M, Hudda N, Ussery D, Kothari A, Jun SR. Study of bloodstream co-infection by vancomycin resistant Enterococcus strains in an inpatient with Acute Lymphocytic Leukemia using Nanopore and Illumina sequencing. Nanopore Community Meeting, 2019.
68. Jenjaroenpun SP, Udaondo Z, Wongsurawat T, Abram K, CourtneyAnderson, Lopez J, Mohan M, Tytarenko R, Walker B, Ussery D, Jun SR, Kothari A. Whole-Genome Analysis of VREfm Isolates with Daptomycin Resistance Using Oxford Nanopore and Illumina Sequencing. American Society of Microbiology, 2019.
69. Udaondo Z, Jenjaroenpun P, Wongsurawat T, Walker B, Anderson C, Lopez J, Mohan M, Hudda NU, Ussery D, Kothari A, Jun S. Study of bloodstream co-infection by Vancomycin Resistant Enterococcus strains in an inpatient with Acute Lymphocytic Leukemia using Oxford Nanopore and Illumina sequencing. Oxford Nanopore meeting, 2019.
70. AJava, Ren Z, Mohan M, Sasapu A, Motwani P, Atkinson J. Familial pregnancy-associated aHUS and acute heart failure. American Society of Nephrology, 2019.
71. Udaondo Z, Wongsurawat T, Jenjaroenpun P, Abram K, Anderson C, Lopez J, Mohan M, Tytarenko R, Walker B, Ussery D, Kothari A, Jun S. Genomic surveillance for nosocomial outbreak with vancomycin-resistant Enterococcus faecium strains from cancer patients with bacteremia and urinary tract infections. Human Genome Meeting, 2019.
72. Mohan M, Meek JC, Meek ME, Broadwater R, Stone K, Greenway A, Alapat D, Rhee FV. Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization, 2018.
73. Yarlagadda N, Krishnan G, Mohan M, Johnsrud A, Wolfe F, Kothari A. Survey of Compliance to Infection Control Measures and Its Impact on Healthcare of Patients in a Hematopoietic Stem Cell Transplant Unit, 2018. e-Pub 2018.
74. Schinke C, Ashby C, Wang Y, Tytarenko R, Boyle E, Wardell C, Qu P, Thanendrarajan S, Susanibar S, Yarlagadda N, Khan M, Mohan M, Zangari M, Rhee FV, Davies F, Barlogie B, Morgan G, Walker B. The Mutational Landscape of Primary Plasma Cell Leukemia. American Society of Hematology, 2018.
75. Kamimoto JJ, Adaniya SS, Mohan M, Jenjaroenpun P, Krishnan G, Crescencio JC, Burgess MJ, Tytarenko R, Emery N, Rosenbaum ER, Walker B, Nookaew I, Kothari A. Severity and outcomes of Toxin negative vs Toxin positive patients with Clostridium Difficile infection. ID Week, 2018.
76. Zangari M, Desai S, Mohan M, Rhee FV, Thanendrarajan S, Schinke C, Davies F, Morgan G, Suva LJ, Yoon D, Rasche L, Weinhold N, Sharma S, Kumar M. Remineralization of Bone Lytic Lesions in high-risk myeloma patients enrolled on total therapy five protocol (TT5); the Arkansas experience. ASMBR Conference, 2018.
77. Zangari M, Weinhold N, Suva L, Mohan M, Yoon D, Davies F, Morgan G, Rhee FV, Thanendararjan S, Schinke C, Kumar M. Refilling of Bony Myeloma Lytic lesion in patients treated on Total Therapy 4 protocol. Molecular Pharmacology and Therapeutics of Bone and other Musculoskeletal Diseases and Cancer and Bone Society 2018 Meeting, 2018.
78. Mohan M, Kothari A, Susanibar-Adaniya SP, Saylors ME, Lusardi KT, Rico Crescencio JC, Burgess MJ. Respiratory Viral Infections in Multiple Myeloma Patients. ID week, 2017.
79. Mohan M, Rhee FV, Thanendrarajan S, Schinke C, Davies FE, Morgan G, Zangari M. Daratumamab in High-Risk Relapse/Refractory Myeloma Patients. Effect of 1q21 Duplication and GEP70 Status. American Society of Hematology meeting, 2017.
80. Schinke C, Deshpande S, Wang H, Carlton V, Kong K, Moorhead M, Willis T, Patel P, Thanendrarajan S, Mohan M, Mathur P, Susanibar S, Hoque S, Radhakrishnan M, Tytarenko R, Stephens O, Rasche L, Rhee FV, Zangari M, Petty N, Alapat D, Johnson S, Epstein J, Barlogie B, Davies F, Hoering A, Weinhold N, Morgan G. Next Generation Sequencing (NGS) based Minimal Residual Disease (MRD) testing is highly predictive of Overall and Progression Free Survival in the Total Therapy Trials and shows different prognostic implications in High vs Standard Risk Multiple Myeloma. American Society of Hematology, 2016.
81. Zangari M, Buros A, Yoon D, Branca A, Schinke C, Thanendrarajan S, Suva LJ, Mohan M, Davies F, Rhee FV, Morgan G. The Expression of PTH1 and PTH2 Receptors in Bone Marrow is Associated with the Progression of Newly Diagnosed Myeloma Patients. American Society of Bone and Mineral Research, 2016.
82. Kothari A, Susanibar-Adaniya SP, Mohan M, Saylors ME, Lusardi KT, Rico Crescencio JC, Burgess MJ, Bariola JR. Bacteremias Following Autologous Stem Cell Transplantation for Hematologic Malignancies and Solid Tumors: Risk Factors and Outcomes. American Society of Microbiology, 2016.
83. Mohan M, Samant R, Suva LJ, Montgomery CO, Alapat DV, Morello R, Rhee FV, Waheed S, Thanendrarajan S, Schinke C, Heuck C, Jethava Y, Johann D, Barlogie B, Davies FE, Gareth. Re-Mineralization of Large Pelvic Lytic Lesions by CT Imaging in Patients with Multiple Myeloma. American Society of Hematology, 2015.
84. Mohan M, Heuck C, Chavan SS, Stein CK, Tytarenko R, Weinhold N, Ali S, Miller VA, Thanendrarajan S, Schinke C, Mohan M, Sawyer J, Peterson EA, Bauer M. Comprehensive Genomic Profiling of Multiple Myeloma during Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations. American Society of Hematology 2015.
85. Advani V, Wietfeldt ED, Mohan M, Margaret Boehler CS, Hassan T, Hassan I. Comparison of endoscopist administered conscious sedation versus anesthesiologist Administered deep sedation for gastrointestinal endoscopy in an ambulatory surgery center. What should be the standard of care?. Digestive disease week 2011.
86. Verhagen, Thalji S, Mohan M, Shreenivas A, Clarke CN, Christians KK, Tsai S, Evans DB, Szabo A, Kothari AN. Risk of Adverse Postoperative Events in Patients Recovered from SARS-CoV-2 Infection Undergoing Pancreas Resection for Cancer: An N3C Study. Society of Asian Academic Surgeons.
87. Thanendrarajan S, Stein CK, Davies FE, Rhee FV, Zangari M, Heuck C, Schinke C, Waheed S, Jethava Y, Weinhold N, Matin A, Mathur P, Mohan M, Radhakrishnan M, Barlogie B. Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. American Society of Hematology 2015.
88. Alhassan S, Abu-sayf A, Arsene C, Mohan M, Fraser B, Ghiarai M, Kuhta T, Krayem H. Suboptimal Implementation of Diagnostic Algorithms and Overuse Of CT-Pulmonary Angiography In Patients With Suspected Pulmonary Embolism: A Retrospective Study. American Thoracic Society 2013.
89. Schinke C, Deshpande S, Mitchell A, Faham M, Patel P, Thanendrarajan S, Mohan M, Mathur P, Matin A, Radhakrishnan M, Tytarenko R, Stephens OW, Rhee FV, Zangari M, Jethava Y. Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. American Society of Hematology 2015.
90. Mohan M, Samant R, Buros A, Alapat D, Walter J, Pait T, Gahleb N, Thanendrarajan S, van Rhee F, Davies F, Morgan G, Schinke C, Suva LJ, Zangari M. Effect of Bone allograft in multiple myeloma spine surgeries. ASMBR Conference.
91. Zangari M, Buros A, Yoon D, Suva LJ, Branca A, Weinhold N, Rasche L, Schinke C, Thanendrarajan S, Mohan M, Davies F, Rhee FV, Morgan G. Parathyroid Hormone Receptor 1 & 2 gene expression from bone marrow biopsy modulates plasma cell GEP derived myeloma survival. American Society of Hematology.
92. Susanibar S, Qu P, Hoering A, Thanendrarajan S, Kamimoto JJ, Mohan M, Mathur P, Hoque S, Radhakrishnan M, Rhee FV, Zangari M, Davies FE, Alapat D, Bart B, Morgan GJ, Schinke CD. Clinical and Molecular Characterization of Primary Plasma Cell Leukemia. American Society of Hematology 2015.

Book Chapters

1. Vasudevan S, Gundarlapalli S, Thalambedu N, Mohan M. Updates in the Management of Multiple Myeloma from the American Society of Hematology Meeting 2021. touchREVIEWS in Oncology & Haematology, 2022.
2. Brown S, Beavers C, Kamaraju S, Mohan M, Fatunde O, Echefu G, Zaharova S, Wallace B, Oxencis C. Principles of Drug Metabolism and Interactions in Cardio-Oncology Drug Metabolism. In: Handbook: Concepts and Applications in Cancer Research 2nd Edition.
3. Mohan M, Hari P, Chhabra S. Immunotherapy - Chimeric Antigen Receptor –T cell and Bispecific T Cell Engager in Multiple Myeloma Expert Clinical Perspective. In: : Controversies and Uncertainties in Diagnosis & Management of Cancer, 2nd Edition.